Cargando…

Validation of Commercial Activity Trackers in Everyday Life of People with Parkinson’s Disease

Maintaining physical activity is an important clinical goal for people with Parkinson’s disease (PwPD). We investigated the validity of two commercial activity trackers (ATs) to measure daily step counts. We compared a wrist- and a hip-worn commercial AT against the research-grade Dynaport Movemonit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ginis, Pieter, Goris, Maaike, De Groef, An, Blondeel, Astrid, Gilat, Moran, Demeyer, Heleen, Troosters, Thierry, Nieuwboer, Alice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144957/
https://www.ncbi.nlm.nih.gov/pubmed/37112496
http://dx.doi.org/10.3390/s23084156
Descripción
Sumario:Maintaining physical activity is an important clinical goal for people with Parkinson’s disease (PwPD). We investigated the validity of two commercial activity trackers (ATs) to measure daily step counts. We compared a wrist- and a hip-worn commercial AT against the research-grade Dynaport Movemonitor (DAM) during 14 days of daily use. Criterion validity was assessed in 28 PwPD and 30 healthy controls (HCs) by a 2 × 3 ANOVA and intraclass correlation coefficients (ICC(2,1)). The ability to measure daily step fluctuations compared to the DAM was studied by a 2 × 3 ANOVA and Kendall correlations. We also explored compliance and user-friendliness. Both the ATs and the DAM measured significantly fewer steps/day in PwPD compared to HCs (p < 0.01). Step counts derived from the ATs showed good to excellent agreement with the DAM in both groups (ICC(2,1) > 0.83). Daily fluctuations were detected adequately by the ATs, showing moderate associations with DAM-rankings. While compliance was high overall, 22% of PwPD were disinclined to use the ATs after the study. Overall, we conclude that the ATs had sufficient agreement with the DAM for the purpose of promoting physical activity in mildly affected PwPD. However, further validation is needed before clinical use can be widely recommended.